Navigation Links
Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
Date:5/1/2008

rther expects gross margin improvement of more than 150 basis points and operating margin improvement of 70 basis points in fiscal 2009.

Adjusted fiscal 2009 guidance excludes $7-8 million, or approximately $0.17-$0.20 per share, of costs to restructure other areas of Haemonetics' business, including manufacturing, quality, R&D, and Europe Phase II.

For the full year 2009, the Company expects to generate $40 million of free cash flow.

Fiscal 2009 GAAP earnings per share guidance is $2.14 to $2.21.

Haemonetics has posted potential income scenarios reflecting guidance ranges as well as potential fiscal 2009 product line growth on its website at http://www.haemonetics.com.

CONFERENCE CALL

Haemonetics will hold a conference call on Thursday, May 1st at 10:00 am Eastern to discuss these results. Interested parties can participate in the conference call by dialing 888-802-8577 (U.S. only) or (973) 935-8754 (International) with conference ID 42384135. The call will be replayed through May 15, 2008 at (800) 642-1687 (U.S. only) or (706) 645-9291 (International) using PIN 42384135.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Haemonetics Webcast Presentation
2. Keiko Hattori Joins Haemonetics as President of Haemonetics Japan
3. Haemonetics Appoints Executive Leadership of European Operations
4. Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 2008
5. Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales
6. Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers
7. Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 2008
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Kurisko practiced in Canada for 13 years under government controlled health ... a free-market economy. In speaking engagements and in his new book, ... of the fragility of such a system and its threat to ... ... -- Lee Kurisko , a diagnostic radiologist from Minnesota, warns ...
(Date:12/14/2009)... of Thousands of New Chronic Hepatitis Infections Annually ... approved by Congress providing for federal funding of ... reduce tens of thousands of new viral hepatitis ... the National Viral Hepatitis Roundtable (NVHR) ... the FY 2010 Consolidated Appropriations bill approved by ...
(Date:12/14/2009)... benefited men whose disease had been treated, hadn,t spread, ... Exercise appears to reduce the risk of death in ... which began in January 1986, included 668 men who,d ... III colon cancer that had not spread (nonmetastatic cancer). ... asked them about any new cancer and disease diagnoses, ...
(Date:12/14/2009)... diabetes and obesity are linked to an increased risk ... insulin glargine (a synthetic insulin preparation marketed under the ... risk of certain cancers than other insulins or oral ... to control for important factors such as obesity that ... other hand, a large randomized trial designed to examine ...
(Date:12/14/2009)... Biopsy , ... Newport News, VA ... that the U.S. Food and Drug Administration (FDA) has granted ... guidance. , , ,GammaLMc® is a complementary technology to ... (GL) system will help doctors accurately locate breast lesions and ...
Breaking Medicine News(10 mins):Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:NVHR Applauds Congressional Action to End Federal Ban on Funding Syringe Exchange 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2
... excipients, these agents include chemicals that can cause nerve ... -- Potentially harmful agents called excipients are contained in ... a U.K. study. , Excipients are used to ... substances or to improve the taste and appearance of ...
... life of foods, manufacturers often add hydrogen to natural ... in the production of trans fats, which ... and increasing the risk for coronary heart disorders. , ... some margarines, crackers, cookies and snacks. Health authorities worldwide ...
... for every ageRICHMOND, Va., Jan. 23 Did you know ... care situation, either their own or with a close family ... number of people who will need long term care in ... that about 9 million Americans over the age of 65 ...
... and Blue Shield,in Wisconsin announced today that its associates ... organizations in 2009 as part of,the company,s annual Associate ... Blue Shield will match 50 percent of associate pledges,increasing ... "Every day our associates work to ...
... experience a nursing shortage that is expected to grow ... research study highlights a pool of potential candidates who ... The study, published in the January/February 2009 issue of ... graduates whose first baccalaureate degree was in nursing with ...
... decreased 3.7 points to 45.7 in December, according to the latest ... Harris Interactive(R) on behalf of Spherion Corporation, indicates that workers are ... to find a new job. , , Results ... Sixty-six percent of workers believe ...
Other Medicine News:Health News:Preemies Exposed to Toxins in Liquid Meds 2Health News:How natural oils can be hydrogenated without making unhealthy trans fats 2Health News:How natural oils can be hydrogenated without making unhealthy trans fats 3Health News:U.S. Government Finds 40% of People Currently Receiving Long Term Care are 18-64; Numbers Continue to Rise 2Health News:U.S. Government Finds 40% of People Currently Receiving Long Term Care are 18-64; Numbers Continue to Rise 3Health News:Anthem Blue Cross and Blue Shield Associates Pledge More Than $900,000 to Community Organizations 2Health News:Anthem Blue Cross and Blue Shield Associates Pledge More Than $900,000 to Community Organizations 3Health News:Nurses with a second degree could impact workforce 2Health News:Texas Employment Report: Employee Confidence Index Drops 2
(Date:12/14/2009)... 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. ... had received a complete response letter from the ... its New Drug Application ("NDA") for Onrigin(TM) (laromustine) ... indicates that the FDA cannot approve the Company,s ... to address remaining issues. ,, Alan Kessman, Chief ...
(Date:12/14/2009)... -- Cancer patients in Finland have gained access ... RapidArc® radiotherapy technology from Varian Medical Systems (NYSE: ... radiotherapy clinic in the Nordic region. Clinicians at ... and precise form of radiotherapy to treat patients ... abdomen and prostate. ,, RapidArc, which enables clinicians ...
(Date:12/14/2009)... 14 According to Millennium Research Group ... intelligence, increased use of safety devices for small-bore ... a key driver of the enteral feeding device ... new US and European Markets for Enteral ... giving set segment will experience the greatest impact ...
Breaking Medicine Technology:Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 1Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 2Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 3Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab 28R 29 Systems for the Cost Efficient Development of Biopharmaceuticals 12812 4Jillian Michaels Americas Toughest Trainer Announces New Line of Weight Loss Supplements 50243 1Jillian Michaels Americas Toughest Trainer Announces New Line of Weight Loss Supplements 50243 2Jillian Michaels Americas Toughest Trainer Announces New Line of Weight Loss Supplements 50243 3Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 1Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 3
... /PRNewswire-FirstCall/ --,Phosphagenics Limited (AIM: PSG) announced today ... 1b clinical trial to demonstrate the,efficacy and ... transdermal,insulin product, TPM-02/Insulin, containing long-acting insulin.,The trial ... quarter of,2007. , TPM-02/Insulin gel is being ...
... to be Part of Data Package Required to ... -- Novavax,Inc. said today that it has received ... ferrets inoculated with its pandemic,influenza vaccine, paving the ... this year. , In the study, ferrets were ...
Other Medicine Technology:Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 2Novavax Reports Positive Pre-Clinical Study Results from Live Virus,Challenge to Pandemic Flu Vaccine 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: